<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.18.0&amp;fc=20230708114047&amp;ff=20240218050839&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.18.0&amp;fc=20230708114047&amp;ff=20240218050839&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0)</generator>
<language>en</language>
<lastbuilddate>Sun, 18 Feb 2024 10:08:42 +0000</lastbuilddate>
<pubDate>Sat, 17 Feb 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>The genetic changes that shaped Neandertals, Denisovans, and modern humans</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38367615/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240218050839&amp;v=2.18.0
      <description>Modern human ancestors diverged from the ancestors of Neandertals and Denisovans about 600,000 years ago. Until about 40,000 years ago, these three groups existed in parallel, occasionally met, and exchanged genes. A critical question is why modern humans, and not the other two groups, survived, became numerous, and developed complex cultures. Here, we discuss genetic differences among the groups and some of their functional consequences. As more present-day genome sequences become available...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Feb 14:S0092-8674(23)01403-4. doi: 10.1016/j.cell.2023.12.029. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Modern human ancestors diverged from the ancestors of Neandertals and Denisovans about 600,000 years ago. Until about 40,000 years ago, these three groups existed in parallel, occasionally met, and exchanged genes. A critical question is why modern humans, and not the other two groups, survived, became numerous, and developed complex cultures. Here, we discuss genetic differences among the groups and some of their functional consequences. As more present-day genome sequences become available from diverse groups, we predict that very few, if any, differences will distinguish all modern humans from all Neandertals and Denisovans. We propose that the genetic basis of what constitutes a modern human is best thought of as a combination of genetic features, where perhaps none of them is present in each and every present-day individual.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38367615/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240218050839&v=2.18.0">38367615</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.12.029>10.1016/j.cell.2023.12.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38367615</guid>
<pubDate>Sat, 17 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Hugo Zeberg</dc:creator>
<dc:creator>Mattias Jakobsson</dc:creator>
<dc:creator>Svante Pääbo</dc:creator>
<dc:date>2024-02-17</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The genetic changes that shaped Neandertals, Denisovans, and modern humans</dc:title>
<dc:identifier>pmid:38367615</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.12.029</dc:identifier>
</item>
<item>
<title>Selection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon-α2a</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38367616/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240218050839&amp;v=2.18.0
      <description>CD4^(+) T cells with latent HIV-1 infection persist despite treatment with antiretroviral agents and represent the main barrier to a cure of HIV-1 infection. Pharmacological disruption of viral latency may expose HIV-1-infected cells to host immune activity, but the clinical efficacy of latency-reversing agents for reducing HIV-1 persistence remains to be proven. Here, we show in a randomized-controlled human clinical trial that the histone deacetylase inhibitor panobinostat, when administered...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Feb 16:S0092-8674(24)00105-3. doi: 10.1016/j.cell.2024.01.037. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CD4<sup>+</sup> T cells with latent HIV-1 infection persist despite treatment with antiretroviral agents and represent the main barrier to a cure of HIV-1 infection. Pharmacological disruption of viral latency may expose HIV-1-infected cells to host immune activity, but the clinical efficacy of latency-reversing agents for reducing HIV-1 persistence remains to be proven. Here, we show in a randomized-controlled human clinical trial that the histone deacetylase inhibitor panobinostat, when administered in combination with pegylated interferon-α2a, induces a structural transformation of the HIV-1 reservoir cell pool, characterized by a disproportionate overrepresentation of HIV-1 proviruses integrated in ZNF genes and in chromatin regions with reduced H3K27ac marks, the molecular target sites for panobinostat. By contrast, proviruses near H3K27ac marks were actively selected against, likely due to increased susceptibility to panobinostat. These data suggest that latency-reversing treatment can increase the immunological vulnerability of HIV-1 reservoir cells and accelerate the selection of epigenetically privileged HIV-1 proviruses.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38367616/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240218050839&v=2.18.0">38367616</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.01.037>10.1016/j.cell.2024.01.037</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38367616</guid>
<pubDate>Sat, 17 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Marie Armani-Tourret</dc:creator>
<dc:creator>Ce Gao</dc:creator>
<dc:creator>Ciputra Adijaya Hartana</dc:creator>
<dc:creator>WeiWei Sun</dc:creator>
<dc:creator>Leah Carrere</dc:creator>
<dc:creator>Liliana Vela</dc:creator>
<dc:creator>Alexander Hochroth</dc:creator>
<dc:creator>Maxime Bellefroid</dc:creator>
<dc:creator>Amy Sbrolla</dc:creator>
<dc:creator>Katrina Shea</dc:creator>
<dc:creator>Theresa Flynn</dc:creator>
<dc:creator>Isabelle Roseto</dc:creator>
<dc:creator>Yelizaveta Rassadkina</dc:creator>
<dc:creator>Carole Lee</dc:creator>
<dc:creator>Francoise Giguel</dc:creator>
<dc:creator>Rajeev Malhotra</dc:creator>
<dc:creator>Frederic D Bushman</dc:creator>
<dc:creator>Rajesh T Gandhi</dc:creator>
<dc:creator>Xu G Yu</dc:creator>
<dc:creator>Daniel R Kuritzkes</dc:creator>
<dc:creator>Mathias Lichterfeld</dc:creator>
<dc:date>2024-02-17</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Selection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon-α2a</dc:title>
<dc:identifier>pmid:38367616</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.01.037</dc:identifier>
</item>
<item>
<title>Tackling metabolic defects in HFpEF</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38367012/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240218050839&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 17:ehad884. doi: 10.1093/eurheartj/ehad884. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38367012/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240218050839&v=2.18.0">38367012</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad884>10.1093/eurheartj/ehad884</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38367012</guid>
<pubDate>Sat, 17 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Rongling Wang</dc:creator>
<dc:creator>Gabriele G Schiattarella</dc:creator>
<dc:date>2024-02-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Tackling metabolic defects in HFpEF</dc:title>
<dc:identifier>pmid:38367012</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad884</dc:identifier>
</item>
<item>
<title>The Canadian Cardiovascular Society Classification of acute atherothrombotic myocardial infarction provides a novel staging scheme based on tissue injury severity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38367011/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240218050839&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 17:ehad821. doi: 10.1093/eurheartj/ehad821. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38367011/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240218050839&v=2.18.0">38367011</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad821>10.1093/eurheartj/ehad821</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38367011</guid>
<pubDate>Sat, 17 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Andreas Kumar</dc:creator>
<dc:creator>Keyur Vora</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Rohan Dharmakumar</dc:creator>
<dc:date>2024-02-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The Canadian Cardiovascular Society Classification of acute atherothrombotic myocardial infarction provides a novel staging scheme based on tissue injury severity</dc:title>
<dc:identifier>pmid:38367011</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad821</dc:identifier>
</item>
<item>
<title>Breathing danger: linking air pollution to cardiovascular disease and increased risk of abdominal aortic aneurysm</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38366825/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240218050839&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 16:ehae092. doi: 10.1093/eurheartj/ehae092. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38366825/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240218050839&v=2.18.0">38366825</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae092>10.1093/eurheartj/ehae092</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38366825</guid>
<pubDate>Sat, 17 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Omar Hahad</dc:creator>
<dc:creator>Andreas Daiber</dc:creator>
<dc:creator>Thomas Münzel</dc:creator>
<dc:date>2024-02-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Breathing danger: linking air pollution to cardiovascular disease and increased risk of abdominal aortic aneurysm</dc:title>
<dc:identifier>pmid:38366825</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae092</dc:identifier>
</item>
<item>
<title>A new dawn of managing cardiovascular risk in obesity: the importance of combining lifestyle intervention and medication</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38366823/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240218050839&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 16:ehae091. doi: 10.1093/eurheartj/ehae091. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38366823/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240218050839&v=2.18.0">38366823</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae091>10.1093/eurheartj/ehae091</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38366823</guid>
<pubDate>Sat, 17 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Martin Halle</dc:creator>
<dc:creator>Michael Papadakis</dc:creator>
<dc:date>2024-02-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A new dawn of managing cardiovascular risk in obesity: the importance of combining lifestyle intervention and medication</dc:title>
<dc:identifier>pmid:38366823</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae091</dc:identifier>
</item>
<item>
<title>Device innovation in cardiovascular medicine: a report from the European Society of Cardiology Cardiovascular Round Table</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38366821/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240218050839&amp;v=2.18.0
      <description>Research performed in Europe has driven cardiovascular device innovation. This includes, but is not limited to, percutaneous coronary intervention, cardiac imaging, transcatheter heart valve implantation, and device therapy of cardiac arrhythmias and heart failure. An important part of future medical progress involves the evolution of medical technology and the ongoing development of artificial intelligence and machine learning. There is a need to foster an environment conducive to medical...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 16:ehae069. doi: 10.1093/eurheartj/ehae069. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Research performed in Europe has driven cardiovascular device innovation. This includes, but is not limited to, percutaneous coronary intervention, cardiac imaging, transcatheter heart valve implantation, and device therapy of cardiac arrhythmias and heart failure. An important part of future medical progress involves the evolution of medical technology and the ongoing development of artificial intelligence and machine learning. There is a need to foster an environment conducive to medical technology development and validation so that Europe can continue to play a major role in device innovation while providing high standards of safety. This paper summarizes viewpoints on the topic of device innovation in cardiovascular medicine at the European Society of Cardiology Cardiovascular Round Table, a strategic forum for high-level dialogue to discuss issues related to the future of cardiovascular health in Europe. Devices are developed and improved through an iterative process throughout their lifecycle. Early feasibility studies demonstrate proof of concept and help to optimize the design of a device. If successful, this should ideally be followed by randomized clinical trials comparing novel devices vs. accepted standards of care when available and the collection of post-market real-world evidence through registries. Unfortunately, standardized procedures for feasibility studies across various device categories have not yet been implemented in Europe. Cardiovascular imaging can be used to diagnose and characterize patients for interventions to improve procedural results and to monitor devices long term after implantation. Randomized clinical trials often use cardiac imaging-based inclusion criteria, while less frequently trials randomize patients to compare the diagnostic or prognostic value of different modalities. Applications using machine learning are increasingly important, but specific regulatory standards and pathways remain in development in both Europe and the USA. Standards are also needed for smart devices and digital technologies that support device-driven biomonitoring. Changes in device regulation introduced by the European Union aim to improve clinical evidence, transparency, and safety, but they may impact the speed of innovation, access, and availability. Device development programmes including dialogue on unmet needs and advice on study designs must be driven by a community of physicians, trialists, patients, regulators, payers, and industry to ensure that patients have access to innovative care.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38366821/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240218050839&v=2.18.0">38366821</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae069>10.1093/eurheartj/ehae069</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38366821</guid>
<pubDate>Sat, 17 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Stephan Windecker</dc:creator>
<dc:creator>Martine Gilard</dc:creator>
<dc:creator>Stephan Achenbach</dc:creator>
<dc:creator>Alain Cribier</dc:creator>
<dc:creator>Victoria Delgado</dc:creator>
<dc:creator>Nataliya Deych</dc:creator>
<dc:creator>Inga Drossart</dc:creator>
<dc:creator>Hélène Eltchaninoff</dc:creator>
<dc:creator>Alan G Fraser</dc:creator>
<dc:creator>Alexandra Goncalves</dc:creator>
<dc:creator>Gerhard Hindricks</dc:creator>
<dc:creator>Richard Holborow</dc:creator>
<dc:creator>Arie Pieter Kappetein</dc:creator>
<dc:creator>John Kilmartin</dc:creator>
<dc:creator>Jana Kurucova</dc:creator>
<dc:creator>Thomas F Lüscher</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Donal B O'Connor</dc:creator>
<dc:creator>Mark Perkins</dc:creator>
<dc:creator>Eigil Samset</dc:creator>
<dc:creator>Ralph Stephan von Bardeleben</dc:creator>
<dc:creator>Franz Weidinger</dc:creator>
<dc:date>2024-02-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Device innovation in cardiovascular medicine: a report from the European Society of Cardiology Cardiovascular Round Table</dc:title>
<dc:identifier>pmid:38366821</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae069</dc:identifier>
</item>
<item>
<title>Inhibiting angiopoietin-like protein 3: clear skies or clouds on the horizon?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38366820/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240218050839&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 16:ehae068. doi: 10.1093/eurheartj/ehae068. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38366820/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240218050839&v=2.18.0">38366820</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae068>10.1093/eurheartj/ehae068</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38366820</guid>
<pubDate>Sat, 17 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Robert A Hegele</dc:creator>
<dc:date>2024-02-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Inhibiting angiopoietin-like protein 3: clear skies or clouds on the horizon?</dc:title>
<dc:identifier>pmid:38366820</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae068</dc:identifier>
</item>
<item>
<title>Anticoagulation in atrial fibrillation and implantable cardioverter defibrillator implantation in arrhythmogenic right ventricular cardiomyopathy: need for improving patient selection</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38366819/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240218050839&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 16;45(7):491-494. doi: 10.1093/eurheartj/ehae070.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38366819/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240218050839&v=2.18.0">38366819</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae070>10.1093/eurheartj/ehae070</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38366819</guid>
<pubDate>Sat, 17 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-02-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Anticoagulation in atrial fibrillation and implantable cardioverter defibrillator implantation in arrhythmogenic right ventricular cardiomyopathy: need for improving patient selection</dc:title>
<dc:identifier>pmid:38366819</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae070</dc:identifier>
</item>
<item>
<title>Correction to: Cardiovascular hospitalizations and mortality among adults aged 25-64 years in the USA</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38366817/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240218050839&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 16:ehae018. doi: 10.1093/eurheartj/ehae018. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38366817/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240218050839&v=2.18.0">38366817</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae018>10.1093/eurheartj/ehae018</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38366817</guid>
<pubDate>Sat, 17 Feb 2024 06:00:00 -0500</pubDate>
<dc:date>2024-02-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: Cardiovascular hospitalizations and mortality among adults aged 25-64 years in the USA</dc:title>
<dc:identifier>pmid:38366817</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae018</dc:identifier>
</item>
<item>
<title>Phospholipids with two polyunsaturated fatty acyl tails promote ferroptosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38366593/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240218050839&amp;v=2.18.0
      <description>Phospholipids containing a single polyunsaturated fatty acyl tail (PL-PUFA(1)s) are considered the driving force behind ferroptosis, whereas phospholipids with diacyl-PUFA tails (PL-PUFA(2)s) have been rarely characterized. Dietary lipids modulate ferroptosis, but the mechanisms governing lipid metabolism and ferroptosis sensitivity are not well understood. Our research revealed a significant accumulation of diacyl-PUFA phosphatidylcholines (PC-PUFA(2)s) following fatty acid or phospholipid...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Feb 8:S0092-8674(24)00067-9. doi: 10.1016/j.cell.2024.01.030. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Phospholipids containing a single polyunsaturated fatty acyl tail (PL-PUFA<sub>1</sub>s) are considered the driving force behind ferroptosis, whereas phospholipids with diacyl-PUFA tails (PL-PUFA<sub>2</sub>s) have been rarely characterized. Dietary lipids modulate ferroptosis, but the mechanisms governing lipid metabolism and ferroptosis sensitivity are not well understood. Our research revealed a significant accumulation of diacyl-PUFA phosphatidylcholines (PC-PUFA<sub>2</sub>s) following fatty acid or phospholipid treatments, correlating with cancer cell sensitivity to ferroptosis. Depletion of PC-PUFA<sub>2</sub>s occurred in aging and Huntington's disease brain tissue, linking it to ferroptosis. Notably, PC-PUFA<sub>2</sub>s interacted with the mitochondrial electron transport chain, generating reactive oxygen species (ROS) for initiating lipid peroxidation. Mitochondria-targeted antioxidants protected cells from PC-PUFA<sub>2</sub>-induced mitochondrial ROS (mtROS), lipid peroxidation, and cell death. These findings reveal a critical role for PC-PUFA<sub>2</sub>s in controlling mitochondria homeostasis and ferroptosis in various contexts and explain the ferroptosis-modulating mechanisms of free fatty acids. PC-PUFA<sub>2</sub>s may serve as diagnostic and therapeutic targets for modulating ferroptosis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38366593/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240218050839&v=2.18.0">38366593</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.01.030>10.1016/j.cell.2024.01.030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38366593</guid>
<pubDate>Sat, 17 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Baiyu Qiu</dc:creator>
<dc:creator>Fereshteh Zandkarimi</dc:creator>
<dc:creator>Carla T Bezjian</dc:creator>
<dc:creator>Eduard Reznik</dc:creator>
<dc:creator>Rajesh Kumar Soni</dc:creator>
<dc:creator>Wei Gu</dc:creator>
<dc:creator>Xuejun Jiang</dc:creator>
<dc:creator>Brent R Stockwell</dc:creator>
<dc:date>2024-02-17</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Phospholipids with two polyunsaturated fatty acyl tails promote ferroptosis</dc:title>
<dc:identifier>pmid:38366593</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.01.030</dc:identifier>
</item>
<item>
<title>High fat intake sustains sorbitol intolerance after antibiotic-mediated Clostridia depletion from the gut microbiota</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38366592/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240218050839&amp;v=2.18.0
      <description>Carbohydrate intolerance, commonly linked to the consumption of lactose, fructose, or sorbitol, affects up to 30% of the population in high-income countries. Although sorbitol intolerance is attributed to malabsorption, the underlying mechanism remains unresolved. Here, we show that a history of antibiotic exposure combined with high fat intake triggered long-lasting sorbitol intolerance in mice by reducing Clostridia abundance, which impaired microbial sorbitol catabolism. The restoration of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Feb 9:S0092-8674(24)00066-7. doi: 10.1016/j.cell.2024.01.029. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Carbohydrate intolerance, commonly linked to the consumption of lactose, fructose, or sorbitol, affects up to 30% of the population in high-income countries. Although sorbitol intolerance is attributed to malabsorption, the underlying mechanism remains unresolved. Here, we show that a history of antibiotic exposure combined with high fat intake triggered long-lasting sorbitol intolerance in mice by reducing Clostridia abundance, which impaired microbial sorbitol catabolism. The restoration of sorbitol catabolism by inoculation with probiotic Escherichia coli protected mice against sorbitol intolerance but did not restore Clostridia abundance. Inoculation with the butyrate producer Anaerostipes caccae restored a normal Clostridia abundance, which protected mice against sorbitol-induced diarrhea even when the probiotic was cleared. Butyrate restored Clostridia abundance by stimulating epithelial peroxisome proliferator-activated receptor-gamma (PPAR-γ) signaling to restore epithelial hypoxia in the colon. Collectively, these mechanistic insights identify microbial sorbitol catabolism as a potential target for approaches for the diagnosis, treatment, and prevention of sorbitol intolerance.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38366592/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240218050839&v=2.18.0">38366592</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.01.029>10.1016/j.cell.2024.01.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38366592</guid>
<pubDate>Sat, 17 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Jee-Yon Lee</dc:creator>
<dc:creator>Connor R Tiffany</dc:creator>
<dc:creator>Scott P Mahan</dc:creator>
<dc:creator>Matthew Kellom</dc:creator>
<dc:creator>Andrew W L Rogers</dc:creator>
<dc:creator>Henry Nguyen</dc:creator>
<dc:creator>Eric T Stevens</dc:creator>
<dc:creator>Hugo L P Masson</dc:creator>
<dc:creator>Kohei Yamazaki</dc:creator>
<dc:creator>Maria L Marco</dc:creator>
<dc:creator>Emiley A Eloe-Fadrosh</dc:creator>
<dc:creator>Peter J Turnbaugh</dc:creator>
<dc:creator>Andreas J Bäumler</dc:creator>
<dc:date>2024-02-17</dc:date>
<dc:source>Cell</dc:source>
<dc:title>High fat intake sustains sorbitol intolerance after antibiotic-mediated Clostridia depletion from the gut microbiota</dc:title>
<dc:identifier>pmid:38366592</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.01.029</dc:identifier>
</item>
<item>
<title>A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38366591/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240218050839&amp;v=2.18.0
      <description>In response to the 2022 outbreak of mpox driven by unprecedented human-to-human monkeypox virus (MPXV) transmission, we designed BNT166, aiming to create a highly immunogenic, safe, accessible, and scalable next-generation vaccine against MPXV and related orthopoxviruses. To address the multiple viral forms and increase the breadth of immune response, two candidate multivalent mRNA vaccines were evaluated pre-clinically: a quadrivalent vaccine (BNT166a; encoding the MPXV antigens A35, B6, M1,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Feb 6:S0092-8674(24)00054-0. doi: 10.1016/j.cell.2024.01.017. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">In response to the 2022 outbreak of mpox driven by unprecedented human-to-human monkeypox virus (MPXV) transmission, we designed BNT166, aiming to create a highly immunogenic, safe, accessible, and scalable next-generation vaccine against MPXV and related orthopoxviruses. To address the multiple viral forms and increase the breadth of immune response, two candidate multivalent mRNA vaccines were evaluated pre-clinically: a quadrivalent vaccine (BNT166a; encoding the MPXV antigens A35, B6, M1, H3) and a trivalent vaccine (BNT166c; without H3). Both candidates induced robust T cell responses and IgG antibodies in mice, including neutralizing antibodies to both MPXV and vaccinia virus. In challenge studies, BNT166a and BNT166c provided complete protection from vaccinia, clade I, and clade IIb MPXV. Furthermore, immunization with BNT166a was 100% effective at preventing death and at suppressing lesions in a lethal clade I MPXV challenge in cynomolgus macaques. These findings support the clinical evaluation of BNT166, now underway (NCT05988203).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38366591/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240218050839&v=2.18.0">38366591</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.01.017>10.1016/j.cell.2024.01.017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38366591</guid>
<pubDate>Sat, 17 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Adam Zuiani</dc:creator>
<dc:creator>Charles L Dulberger</dc:creator>
<dc:creator>Nilushi S De Silva</dc:creator>
<dc:creator>Meghan Marquette</dc:creator>
<dc:creator>Yu-Jung Lu</dc:creator>
<dc:creator>Gavin M Palowitch</dc:creator>
<dc:creator>Anja Dokic</dc:creator>
<dc:creator>Ricardo Sanchez-Velazquez</dc:creator>
<dc:creator>Katja Schlatterer</dc:creator>
<dc:creator>Sanjay Sarkar</dc:creator>
<dc:creator>Swagata Kar</dc:creator>
<dc:creator>Bhavna Chawla</dc:creator>
<dc:creator>Alibek Galeev</dc:creator>
<dc:creator>Claudia Lindemann</dc:creator>
<dc:creator>Daniel A Rothenberg</dc:creator>
<dc:creator>Huitian Diao</dc:creator>
<dc:creator>Alexandra C Walls</dc:creator>
<dc:creator>Theresa A Addona</dc:creator>
<dc:creator>Federico Mensa</dc:creator>
<dc:creator>Annette B Vogel</dc:creator>
<dc:creator>Lynda M Stuart</dc:creator>
<dc:creator>Robbert van der Most</dc:creator>
<dc:creator>John R Srouji</dc:creator>
<dc:creator>Özlem Türeci</dc:creator>
<dc:creator>Richard B Gaynor</dc:creator>
<dc:creator>Uğur Şahin</dc:creator>
<dc:creator>Asaf Poran</dc:creator>
<dc:date>2024-02-17</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease</dc:title>
<dc:identifier>pmid:38366591</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.01.017</dc:identifier>
</item>
<item>
<title>Left Valsalva sinus isolation with Vieussens' arterial ring</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38366258/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240218050839&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 15:ehae074. doi: 10.1093/eurheartj/ehae074. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38366258/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240218050839&v=2.18.0">38366258</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae074>10.1093/eurheartj/ehae074</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38366258</guid>
<pubDate>Sat, 17 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Simin Lin</dc:creator>
<dc:creator>Hongwei Zhang</dc:creator>
<dc:creator>Zihao Li</dc:creator>
<dc:date>2024-02-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Left Valsalva sinus isolation with Vieussens' arterial ring</dc:title>
<dc:identifier>pmid:38366258</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae074</dc:identifier>
</item>
<item>
<title>Stellate ganglion blockade for the management of ventricular arrhythmia storm</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38366239/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240218050839&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 15:ehae083. doi: 10.1093/eurheartj/ehae083. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38366239/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240218050839&v=2.18.0">38366239</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae083>10.1093/eurheartj/ehae083</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38366239</guid>
<pubDate>Sat, 17 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Varun Malik</dc:creator>
<dc:creator>Kalyanam Shivkumar</dc:creator>
<dc:date>2024-02-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Stellate ganglion blockade for the management of ventricular arrhythmia storm</dc:title>
<dc:identifier>pmid:38366239</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae083</dc:identifier>
</item>
<item>
<title>Injury minimization after myocardial infarction: focus on extracellular vesicles</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38366191/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240218050839&amp;v=2.18.0
      <description>Despite improvements in clinical outcomes following acute myocardial infarction, mortality remains high, especially in patients with severely reduced left ventricular ejection fraction (LVEF &lt;30%), emphasizing the need for effective cardioprotective strategies adjunctive to recanalization. Traditional cell therapy has shown equivocal success, shifting the focus to innovative cardioactive biologicals and cell mimetic therapies, particularly extracellular vesicles (EVs). EVs, as carriers of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 15:ehae089. doi: 10.1093/eurheartj/ehae089. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Despite improvements in clinical outcomes following acute myocardial infarction, mortality remains high, especially in patients with severely reduced left ventricular ejection fraction (LVEF &lt;30%), emphasizing the need for effective cardioprotective strategies adjunctive to recanalization. Traditional cell therapy has shown equivocal success, shifting the focus to innovative cardioactive biologicals and cell mimetic therapies, particularly extracellular vesicles (EVs). EVs, as carriers of non-coding RNAs and other essential biomolecules, influence neighbouring and remote cell function in a paracrine manner. Compared to cell therapy, EVs possess several clinically advantageous traits, including stability, ease of storage (enabling off-the-shelf clinical readiness), and decreased immunogenicity. Allogeneic EVs from mesenchymal and/or cardiac stromal progenitor cells demonstrate safety and potential efficacy in preclinical settings. This review delves into the translational potential of EV-based therapeutic approaches, specifically highlighting findings from large-animal studies, and offers a synopsis of ongoing early-stage clinical trials in this domain.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38366191/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240218050839&v=2.18.0">38366191</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae089>10.1093/eurheartj/ehae089</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38366191</guid>
<pubDate>Sat, 17 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Lucio Barile</dc:creator>
<dc:creator>Eduardo Marbán</dc:creator>
<dc:date>2024-02-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Injury minimization after myocardial infarction: focus on extracellular vesicles</dc:title>
<dc:identifier>pmid:38366191</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae089</dc:identifier>
</item>
<item>
<title>A rare case of haemorrhagic left atrial bouncing ball myxoma</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38366073/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240218050839&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 15:ehae064. doi: 10.1093/eurheartj/ehae064. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38366073/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240218050839&v=2.18.0">38366073</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae064>10.1093/eurheartj/ehae064</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38366073</guid>
<pubDate>Sat, 17 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Heng Zhang</dc:creator>
<dc:creator>Xuelian Ao</dc:creator>
<dc:creator>Haige Zhao</dc:creator>
<dc:date>2024-02-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A rare case of haemorrhagic left atrial bouncing ball myxoma</dc:title>
<dc:identifier>pmid:38366073</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae064</dc:identifier>
</item>
<item>
<title>Efficacy of paclitaxel-coated balloon angioplasty combined with intensive lipid-lowering therapy for ST-segment elevation myocardial infarction: insights from near-infrared spectroscopy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38366009/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240218050839&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 15:ehae073. doi: 10.1093/eurheartj/ehae073. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38366009/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240218050839&v=2.18.0">38366009</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae073>10.1093/eurheartj/ehae073</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38366009</guid>
<pubDate>Fri, 16 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Kensaku Nishihira</dc:creator>
<dc:creator>Yuya Asano</dc:creator>
<dc:creator>Yoshisato Shibata</dc:creator>
<dc:date>2024-02-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Efficacy of paclitaxel-coated balloon angioplasty combined with intensive lipid-lowering therapy for ST-segment elevation myocardial infarction: insights from near-infrared spectroscopy</dc:title>
<dc:identifier>pmid:38366009</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae073</dc:identifier>
</item>
<item>
<title>Machine perfusion of marginal donor hearts: a valuable tool, but where and for whom?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38366005/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240218050839&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 15:ehae063. doi: 10.1093/eurheartj/ehae063. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38366005/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240218050839&v=2.18.0">38366005</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae063>10.1093/eurheartj/ehae063</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38366005</guid>
<pubDate>Fri, 16 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Brian Wayda</dc:creator>
<dc:date>2024-02-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Machine perfusion of marginal donor hearts: a valuable tool, but where and for whom?</dc:title>
<dc:identifier>pmid:38366005</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae063</dc:identifier>
</item>
<item>
<title>Fish bone ingestion causes aortic pseudoaneurysm</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38365992/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240218050839&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 15:ehae072. doi: 10.1093/eurheartj/ehae072. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38365992/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240218050839&v=2.18.0">38365992</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae072>10.1093/eurheartj/ehae072</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38365992</guid>
<pubDate>Fri, 16 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Hui Liu</dc:creator>
<dc:creator>Hongwei Zhang</dc:creator>
<dc:creator>Zihao Li</dc:creator>
<dc:date>2024-02-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Fish bone ingestion causes aortic pseudoaneurysm</dc:title>
<dc:identifier>pmid:38365992</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae072</dc:identifier>
</item>
<item>
<title>Aspiration as inspiration for uncommon infective endocarditis treatment</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38365976/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240218050839&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 15:ehae075. doi: 10.1093/eurheartj/ehae075. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38365976/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240218050839&v=2.18.0">38365976</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae075>10.1093/eurheartj/ehae075</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38365976</guid>
<pubDate>Fri, 16 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Sébastien Selleslag</dc:creator>
<dc:creator>Johan Ghekiere</dc:creator>
<dc:creator>Philippe Debonnaire</dc:creator>
<dc:date>2024-02-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Aspiration as inspiration for uncommon infective endocarditis treatment</dc:title>
<dc:identifier>pmid:38365976</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae075</dc:identifier>
</item>





























</channel>
</rss>